Genmab — Juli 2014
-
Tror også man som udgangspunkt skal holde forventningerne nede til Arzerra, men kommer den rigtige partner ind og vil bruge penge på skidtet, så kan det kaste gode royalties af til Genmab. GSK er bare ikke den rigtige partner - og så må vi håbe at Novartis er det eller evt. Gilead vil være med på den ene eller anden måde
-
Solsen Gilead har ansøgt så vidt jeg ved
-
-
-
ja det er second line. samme indikation som idelalisib+ofa phase III køres i
-
Solsen se nu mit link. Der står da direkte at de har sendt NDA for Idelalisib + Rituxan i Relapsed CLL patients ?
-
the
company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of
idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of indolent non-Hodgkin’s lymphoma (iNHL).
The data submitted in this NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab
and to alkylating-agent-containing chemotherapy. -
Content not found
Terrapinn is a global events company. Our events promote innovation and technology that changes people's lives. We partner with the world's leading companies and innovators to make a difference.
(www.terrapinn.com)
-
-
tak for det gentogen
-
Var sikker på at det var Rituxan+Idealisib men kan godt læse nu at det ser ud til at være idelalisib i mono
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind